SUBSCRIBE
SUBSCRIBE
News   FDA

Helicon Group Secures Milestone Regulatory Approval In China For Skin Regeneration Medical Technology ReCell(R)

July 3, 2008 | 
1 min read

Perth, July 3, 2008 (ABN Newswire) - HELICON GROUP LIMITED (ASX:HCG) today announced that the Chinese State Food and Drug Administration (SFDA) has granted approval for the skin regeneration concept and device, ReCell(R).

FDA Approvals Australia
MORE ON THIS TOPIC
Novo Nordisk advertising flags and logo on facade
Regulatory
Novo Nordisk Snags Kidney Disease Expansion for Ozempic in Europe
December 12, 2024
 · 
1 min read
 · 
Kate Goodwin
Mental health, illness ,brain development ,medical treatment concept, messy lines of thinks in human head , vector illustration
Neurodegenerative disease
UniQure Clears Path to Accelerated Approval for Huntington’s Gene Therapy
December 10, 2024
 · 
2 min read
 · 
Tristan Manalac
A scientist with pill bottles in front of FDA headquarters
Regulatory
FDA Action Alert: Ionis, Lexicon, Bristol Myers Squibb and More
December 9, 2024
 · 
7 min read
 · 
Tristan Manalac
Contemporary collage with a running clock and an arrow. Planning and time management concept.
Regulatory
FDA Outlines Accelerated Review Guidelines in Waning Days of Biden Administration
December 6, 2024
 · 
3 min read
 · 
Annalee Armstrong